Lactobacillus salivarius REN inhibits rat oral cancer induced by 4-nitroquioline 1-oxide

Cancer Prevention Research

Volumn 6, Issue 7, 2013, Pages 686-694

  Zhang, Ming ^a   Wang, Fang ^a   Jiang, Lu ^a   Liu, Ruihai ^b   Zhang, Lian ^b   Lei, Xingen ^c   Li, Jiyou ^b   Jiang, Jingli ^a   Guo, Huiyuan ^a   Fang, Bing ^a   Zhao, Liang ^a   Ren, Fazheng ^a  

^a CHINA AGRICULTURAL UNIVERSITY   (China)

^b PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^c Department of Obstetrics Gynecology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 NITROQUIOLINE 1 OXIDE; CARCINOGEN; CYCLINE; CYCLOOXYGENASE 2; PROBIOTIC AGENT; UNCLASSIFIED DRUG; 4 NITROQUINOLINE 1 OXIDE; PTGS2 PROTEIN, RAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL PROLIFERATION; DNA DAMAGE; DOSE RESPONSE; DOWN REGULATION; DRUG ISOLATION; DRUG MEGADOSE; IN VITRO STUDY; IN VIVO STUDY; LACTOBACILLUS SALIVARIUS; LESIONS AND DEFECTS; MALE; MOUTH CANCER; NONHUMAN; OXIDATIVE STRESS; PARANEOPLASTIC SYNDROME; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TONGUE TUMOR; ANIMAL; CHEMICALLY INDUCED; DRUG EFFECTS; ENZYME IMMUNOASSAY; FISCHER 344 RAT; GROWTH, DEVELOPMENT AND AGING; ISOLATION AND PURIFICATION; LACTOBACILLUS; METABOLISM; MOUTH NEOPLASMS; PATHOLOGY; TOXICITY; TUMOR CELL CULTURE; WESTERN BLOTTING;

4-NITROQUINOLINE-1-OXIDE; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CARCINOGENS; CELL PROLIFERATION; CYCLOOXYGENASE 2; DNA DAMAGE; IMMUNOENZYME TECHNIQUES; LACTOBACILLUS; MALE; MOUTH NEOPLASMS; PROBIOTICS; RATS; RATS, INBRED F344; TUMOR CELLS, CULTURED;

EID: 84880081945     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-12-0427     Document Type: Article

References (43)

1. Lee KW, Bode AM, Dong Z. Molecular targets of phytochemicals for cancer prevention. Nat Rev Cancer 2011;11:211-8.
2. Sporn MB. Approaches to prevention of epithelial cancer during the preneoplastic period. Cancer Res 1976;36:2699-702.
3. Wattenberg LW. Chemoprevention of cancer. Cancer Res 1985;45: 1-8.
4. Cerella C, Sobolewski C, Dicato M, Diederich M. Targeting COX-2 expression by natural compounds: a promising alternative strategy to synthetic COX-2 inhibitors for cancer chemoprevention and therapy. Biochem Pharmacol 2010;80:1801-15.
5. FitzGerald GA. COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov 2003;2:879-90.
6. Flower RJ. The development of COX2 inhibitors. Nat Rev Drug Discov 2003;2:179-91.
7. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-102.
8. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-80.
9. Kau AL, Ahern PP, Griffin NW, Goodman AL, Gordon JI. Human nutrition, the gut microbiome and the immune system. Nature 2011;474:327-36.
10. Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, et al. Enterotypes of the human gut microbiome. Nature 2011;473: 174-80.
11. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature 2006;444:1022-3.
12. Chen W, Liu F, Ling Z, Tong X, Xiang C. Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer. PLoS ONE 2012;7:e39743.
13. Iannitti T, Palmieri B. Therapeutical use of probiotic formulations in clinical practice. Clin Nutr 2010;29:701-25.
14. Reddy BS. Prevention of colon cancer by pre- and probiotics: evidence from laboratory studies. Br J Nutr 1998;80:S219-23.
15. Singh J, Rivenson A, Tomita M, Shimamura S, Ishibashi N, Reddy BS. Bifidobacterium longum, a lactic acid-producing intestinal bacterium inhibits colon cancer and modulates the intermediate biomarkers of colon carcinogenesis. Carcinogenesis 1997;18:833-41.
16. Commane D, Hughes R, Shortt C, Rowland I. The potential mechanisms involved in the anti-carcinogenic action of probiotics. Mutat Res 2005;591:276-89.
17. Galdeano CM, Perdigon G. The probiotic bacterium Lactobacillus casei induces activation of the gut mucosal immune system through innate immunity. Clin Vaccine Immunol 2006;13:219-26.
18. Liong MT. Roles of probiotics and prebiotics in colon cancer prevention: Postulated mechanisms and in-vivo evidence. Int J Mol Sci 2008;9:854-63.
19. Wang F, Jiang L, Liu AP, Guo XH, Ren FZ. Analysis of antigenotoxicity of Lactobacillus salivarius by high performance liquid chromatography. Chinese J Anal Chem 2008;36:740-4.
20. Banoczy J, Csiba A. Occurrence of epithelial dysplasia in oral leukoplakia. Analysis and follow-up study of 12 cases. Oral Surg Oral Med Oral Pathol 1976;42:766-74.
21. Kramer IR, Lucas RB, Pindborg JJ, Sobin LH. Definition of leukoplakia and related lesions: an aid to studies on oral precancer. Oral Surg Oral Med Oral Pathol 1978;46:518-39.
22. Yoshida K, Tanaka T, Hirose Y, Yamaguchi F, Kohno H, Toida M, et al. Dietary garcinol inhibits 4-nitroquinoline 1-oxide-induced tongue carcinogenesis in rats. Cancer Lett 2005;221:29-39.
23. Yoshida K, Hirose Y, Tanaka T, Yamada Y, Kuno T, Kohno H, et al. Inhibitory effects of troglitazone, a peroxisome proliferator-activated receptor gamma ligand, in rat tongue carcinogenesis initiated with 4- nitroquinoline 1-oxide. Cancer Sci 2003;94:365-71.
24. Tanaka T, Tanaka M. Oral carcinogenesis and oral cancer chemoprevention: a review. Patholog Res Int 2011;2011:431246.
25. Kanojia D, Vaidya MM. 4-nitroquinoline-1-oxide induced experimental oral carcinogenesis. Oral Oncol 2006;42:655-67.
26. Miranda SR, Noguti J, Carvalho JG, Oshima CT, Ribeiro DA. Oxidative DNA damage is a preliminary step during rat tongue carcinogenesis induced by 4-nitroquinoline 1-oxide. J Mol Histol 2011;42:181-6.
27. Tamae K, Kawai K, Yamasaki S, Kawanami K, Ikeda M, Takahashi K, et al. Effect of age, smoking and other lifestyle factors on urinary 7- methylguanine and 8-hydroxydeoxyguanosine. Cancer Sci 2009;100: 715-21.
28. Kohda K, Tada M, Hakura A, Kasai H, Kawazoe Y. Formation of 8- hydroxyguanine residues in DNA treated with 4-hydroxyaminoquinoline 1-oxide and its related compounds in the presence of seryl-AMP. Biochem Biophys Res Commun 1987;149:1141-8.
29. Burns AJ, Rowland IR. Antigenotoxicity of probiotics and prebiotics on faecal water-induced DNA damage in human colon adenocarcinoma cells. Mutat Res 2004;551:233-43.
30. Wollowski I, Rechkemmer G, Pool-Zobel BL. Protective role of probiotics and prebiotics in colon cancer. Am J Clin Nutr 2001;73: 451S-5S.
31. Surh YJ, Chun KS, Cha HH, Han SS, Keum YS, Park KK, et al. Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation. Mutat Res 2001;480-481:243-68.
32. Backlund MG, Mann JR, Wang D, Dubois RN. Ras up-regulation of cyclooxygenase-2. Methods Enzymol 2006;407:401-10.
33. Chan G, Boyle JO, Yang EK, Zhang F, Sacks PG, Shah JP, et al. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res 1999;59: 991-4.
34. Jung TT, Berlinger NT, Juhn SK. Prostaglandins in squamous cell carcinoma of the head and neck: a preliminary study. Laryngoscope 1985;95:307-12.
35. Shiotani H, Denda A, Yamamoto K, Kitayama W, Endoh T, Sasaki Y, et al. Increased expression of cyclooxygenase-2 protein in 4-nitroquinoline- 1-oxide-induced rat tongue carcinomas and chemopreventive efficacy of a specific inhibitor, nimesulide. Cancer Res 2001;61: 1451-6.
36. Amdekar S, Singh V, Singh R, Sharma P, Keshav P, Kumar A. Lactobacillus casei reduces the inflammatory joint damage associated with collagen-induced arthritis (CIA) by reducing the pro-inflammatory cytokines: Lactobacillus casei: COX-2 inhibitor. J Clin Immunol 2011;31:147-54.
37. Peran L, Camuesco D, Comalada M, Bailon E, Henriksson A, Xaus J, et al. A comparative study of the preventative effects exerted by three probiotics, Bifidobacterium lactis, Lactobacillus casei and Lactobacillus acidophilus, in the TNBS model of rat colitis. J Appl Microbiol 2007;103:836-44.
38. Marnett LJ. The COXIB experience: a look in the rearview mirror. Annu Rev Pharmacol Toxicol 2009;49:265-90.
39. Funk CD, FitzGerald GA. COX-2 inhibitors and cardiovascular risk. J Cardiovasc Pharmacol 2007;50:470-9.
40. Rouzer CA, Marnett LJ. Cyclooxygenases: structural and functional insights. J Lipid Res 2009;50 SUPPL.:S29-34.
41. Chen CC, Lin WC, Kong MS, Shi HN, Walker WA, Lin CY, et al. Oral inoculation of probiotics Lactobacillus acidophilus NCFM suppresses tumour growth both in segmental orthotopic colon cancer and extraintestinal tissue. Br J Nutr 2012;107:1623-34.
42. Lan A, Bruneau A, Bensaada M, Philippe C, Bellaud P, Rabot S, et al. Increased induction of apoptosis by Propionibacterium freudenreichii TL133 in colonic mucosal crypts of human microbiota-associated rats treated with 1, 2-dimethylhydrazine. Br J Nutr 2008;100:1251-9.
43. Foo NP, Ou Yang H, Chiu HH, Chan HY, Liao CC, Yu CK, et al. Probiotics prevent the development of 1, 2-dimethylhydrazine (DMH)-induced colonic tumorigenesis through suppressed colonic mucosa cellular proliferation and increased stimulation of macrophages. J Agric Food Chem 2011;59:13337-45.